Please use this identifier to cite or link to this item: https://apo.ansto.gov.au/dspace/handle/10238/3199
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDenoyer, Den_AU
dc.contributor.authorGreguric, Ien_AU
dc.contributor.authorRoselt, Pen_AU
dc.contributor.authorNeels, OCen_AU
dc.contributor.authorAide, Nen_AU
dc.contributor.authorTaylor, SRen_AU
dc.contributor.authorKatsifis, Aen_AU
dc.contributor.authorDorow, DSen_AU
dc.contributor.authorHicks, RJen_AU
dc.date.accessioned2010-04-19T03:47:12Zen_AU
dc.date.accessioned2010-04-30T05:08:35Z-
dc.date.available2010-04-19T03:47:12Zen_AU
dc.date.available2010-04-30T05:08:35Z-
dc.date.issued2010-03en_AU
dc.identifier.citationDenoyer, D., Greguric, I., Roselt, P., Neels, O. C., Aide, N., Taylor, S. R., Katsifis, A., Dorow, D. S., & Hicks, R. J. (2010). High-contrast PET of melanoma using F-18-MEL050, a selective probe for melanin with predominantly renal clearance. Journal of Nuclear Medicine, 51(3), 441-447. doi:10.2967/jnumed.109.070060en_AU
dc.identifier.govdoc1552-
dc.identifier.issn0161-5505en_AU
dc.identifier.urihttp://dx.doi.org/10.2967/jnumed.109.070060en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/3199en_AU
dc.description.abstractThe aim of this study was to evaluate the novel probe 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide (18F-MEL050) for the imaging of primary and metastatic melanoma. Methods: PET using 18F-MEL050 was performed in murine models of melanoma. The specificity of 18F-MEL050 was studied by comparing its accumulation in pigmented B16-F0 allograft tumors with that of human amelanotic A375 xenografts using PET and high-resolution autoradiography. 18F-MEL050 PET results were compared with 18F-FDG PET, the current standard in melanoma molecular imaging. To test the ability of 18F-MEL050 to assess the metastatic spread of melanoma, a murine model of lung metastasis was imaged by PET/CT, and results correlated with physical assessment of tumor burden in the lungs. Results: In pigmented B16-F0 grafts, 18F-MEL050 PET yielded a tumor-to-background ratio of approximately 20:1 at 1 h and greater than 50:1 at 2 and 3 h. In the B16-F0 melanoma allograft model, tumor-to-background ratio was more than 9-fold higher for 18F-MEL050 than for 18F-FDG (50.9 ± 6.9 vs. 5.8 ± 0.5). No uptake was observed in the amelanotic melanoma xenografts. Intense uptake of 18F-MEL050 was evident in metastatic lesions in the lungs of B16-BL6 tumor–bearing mice on PET at 2 h after tracer injection, with high concordance between 18F-MEL050 accumulation on PET/CT and tumor burden determined at necroscopy. Conclusion: 18F-MEL050 has a rapid tumor uptake and high retention with specificity for melanin, suggesting great potential for noninvasive clinical evaluation of suspected metastatic melanoma. © 2010, Society of Nuclear Medicineen_AU
dc.language.isoenen_AU
dc.publisherSociety of Nuclear Medicineen_AU
dc.subjectNeoplasmsen_AU
dc.subjectMelaninen_AU
dc.subjectRenal clearanceen_AU
dc.subjectPositron computed tomographyen_AU
dc.subjectLungsen_AU
dc.subjectMiceen_AU
dc.titleHigh-contrast PET of melanoma using F-18-MEL050, a selective probe for melanin with predominantly renal clearance.en_AU
dc.typeJournal Articleen_AU
dc.date.statistics2010-03en_AU
Appears in Collections:Journal Articles

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.